Polyrizon Ltd

Company Overview

Business Model: Polyrizon Ltd. is a development stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays. Its core value proposition is to create a thin hydrogel-based shield containment barrier in the nasal cavity. The company operates two primary technology platforms: Capture and Contain (C&C) for physical barrier applications against viruses and allergens, and Trap and Target (T&T) for intranasal delivery of Active Pharmaceutical Ingredients (APIs) with sustained release. The company has not yet generated revenue from product sales.

Market Position: Polyrizon Ltd. operates in the intensely competitive medical device and pharmaceutical industries, characterized by rapid technological change. The company's C&C technology aims to address unmet needs in allergic rhinitis and nasal viral infections (COVID-19, influenza), positioning itself with non-invasive, fast-acting, non-irritant, non-drip, and long-lasting protection (up to 6 hours). The T&T technology targets improved intranasal drug delivery for local and systemic applications, including corticosteroids, benzodiazepines, and naloxone. The company's competitive advantage is its novel hydrogel technology, comprised of naturally occurring, GRAS-by-FDA mucoadhesive polymers.

Recent Strategic Developments:

• Initial Public Offering (October 2024): Closed an IPO of 958,903 units at $4.38 per unit, raising aggregate gross proceeds of $4,199,995.
• SciSparc License Agreement (August 2024): Entered into an exclusive, worldwide, royalty-bearing license agreement with SciSparc Ltd. for its SCI-160 platform to research, develop, and commercialize for pain treatment in humans. This agreement includes milestone payments up to $3.32 million and a 5% royalty on net sales.
• Eurofins Master Services Agreement (November 2024): Engaged Eurofins Amatsiaquitaine S.A.S., a European-based GMP manufacturer, for services including the supply of clinical trial material (CTM) for PL-14 allergy blocker.
• T&T Platform Development: Initiated preclinical studies in March 2025 for intranasal administration of Naloxone in collaboration with Professor Fabio Sonvico. Feasibility studies for corticosteroids, benzodiazepines, and naloxone are planned from Q4 2024 through Q1 2026, with preclinical studies for leading T&T candidates expected in Q2 2026 and Phase I clinical trials in Q4 2027, subject to financing.
• C&C Platform Development: PL-14 (Nasal Allergies Blocker) preclinical safety trials scheduled for Q2 2025, with pivotal clinical trials in Q4 2025, followed by a 510(k) application to the FDA. PL-15 (COVID-19 Blocker) and PL-16 (Influenza Blocker) preclinical safety trials scheduled for Q2 2025, with feasibility clinical trials in Q3 2026 (PL-15) and Q1 2026 (PL-16), and pivotal clinical trials in Q2 2027 (PL-15) and Q3 2026 (PL-16), subject to $2 million in additional financing for each.

Geographic Footprint: Polyrizon Ltd. is incorporated under the laws of the State of Israel. Its principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel. The company also leases space in Rehovot, Israel, for its research and development facility and laboratory. The business strategy incorporates potentially significant international expansion, particularly in anticipation of product candidate approval in the United States and the European Union.

Cross-Border Operations:

• International Subsidiaries: The company currently has no subsidiaries.
• Joint Ventures: Not explicitly detailed in the filing.
• Licensing Agreements: Exclusive, worldwide, royalty-bearing license agreement with SciSparc Ltd. for its SCI-160 platform.
• Regulatory Compliance Across Jurisdictions: Pursuing FDA clearance/approval in the United States (510(k) for PL-14, De Novo Classification for PL-15 and PL-16) and compliance with EU Medical Devices Regulation (CE Mark) for market access in the European Union. Operations are also subject to Israeli regulatory requirements.
• Israeli Innovation Authority (IIA) Grants: Received royalty-bearing grants totaling $620,000 from 2007-2010. Contingent liabilities for these grants were $762,000 as of March 10, 2025, requiring royalties (3%-4.5%) on sales of IIA-developed products. Restrictions apply to transferring manufacturing or know-how outside of Israel without IIA approval, potentially incurring increased royalties or redemption fees.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no revenue)
• Operating Margin: (Negative)
• Net Margin: (Negative)

Investment in Growth:

• R&D Expenditure: $534 thousand (increased by 60.8% from $332 thousand in 2023)
• Capital Expenditures: $0 (no purchases of property and equipment in 2024)
• Strategic Investments: $3,000 thousand (fair value of commitment to SciSparc Ltd. for SCI-160 platform license, paid in shares and warrants)

Currency Impact Analysis:

• Functional currency: U.S. dollar.
• Expenses are incurred in U.S. dollars, Euros, and New Israeli Shekels.
• Foreign exchange impact on revenue and earnings: Exchange rate differences resulted in a $(4) thousand impact in 2024, compared to $11 thousand in 2023.
• Hedging strategies and effectiveness: Not explicitly detailed in the filing.
• Functional currency considerations: The U.S. dollar is the currency of the primary economic environment in which the company operates.

Business Segment Analysis

Nasal Gel Technology (C&C and T&T Platforms)

Financial Performance:

• Revenue: $0 (0% YoY)
• Operating Margin: (Negative)
• Key Growth Drivers: Addressing unmet medical needs in allergic rhinitis, viral infections (COVID-19, influenza), and targeted intranasal drug delivery. The non-invasive, fast-acting, and long-lasting physical barrier properties of C&C, and the sustained release and improved bioavailability potential of T&T, are key drivers.

Product Portfolio:

• Capture and Contain (C&C) Product Candidates:
  • PL-14 – Nasal Allergies Blocker: Expected to be a Class II medical device, pursuing 510(k) pathway. Preclinical safety trials in Q2 2025, pivotal clinical trials in Q4 2025.
  • PL-15 – COVID-19 Blocker: Expected to be a Class II medical device, pursuing De Novo Classification pathway. Preclinical safety trials in Q2 2025, feasibility clinical trials in Q3 2026, pivotal clinical trials in Q2 2027 (subject to $2 million financing).
  • PL-16 – Influenza Blocker: Expected to be a Class II medical device, pursuing De Novo Classification pathway. Preclinical safety trials in Q2 2025, feasibility clinical trials in Q1 2026, pivotal clinical trials in Q3 2026 (subject to $2 million financing).
• Trap and Target (T&T) Product Candidates:
  • Corticosteroids: Feasibility studies Q4 2024 - Q1 2026.
  • Benzodiazepines: Feasibility studies Q4 2024 - Q1 2026.
  • Naloxone – Opioid Antagonist: Preclinical studies initiated March 2025. Feasibility studies Q4 2024 - Q1 2026.
  • SCI-160 – Pain solution: Initial testing to explore potential when combined with T&T technology in Q1 2025, under an exclusive license agreement with SciSparc Ltd.

Market Dynamics:

• Competitive Positioning: Faces competition from existing therapies (vaccination, immunotherapy, face masks, symptom treatments) and other nasal barrier products (e.g., Alzair, Nasalese, Bentrio). In T&T, competes with established pharmaceutical companies in INCS (Sanofi, GlaxoSmithKline plc.), intranasal benzodiazepines (UCB Biopharma SPRL with Nayzilam®), and intranasal naloxone (Emergent BioSolutions, Pfizer, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Opiant Pharmaceuticals, Nasus Pharma, Amphastar Pharmaceuticals, Indivior PLC, Samarth Pharma Pvt. Ltd., Troikaa Pharmaceuticals Ltd., Neon Laboratories Limited).
• Key Customer Types and Regional Market Trends: Targets patients suffering from allergies, viral infections, and those requiring local or systemic drug delivery via nasal route. Market trends include rising infections and allergic conditions, increasing prevalence of respiratory disorders, and growing patient preference for non-invasive, easy-to-administer nasal drug delivery.
• Regulatory Environment by Jurisdiction: Primarily focused on FDA (US) and EU Medical Devices Regulation (EU) for C&C, and FDA 505(b)(2) pathway for T&T.

Geographic Revenue Distribution:

• Not applicable: The company has not generated any revenue from product sales to date.
• Growth Markets: Focus on obtaining regulatory approvals in the United States and the European Union, which represent significant target markets for its product candidates.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries: Polyrizon Ltd. currently has no subsidiaries.
• Joint Ventures: Not explicitly detailed in the filing.
• Licensing Agreements: Exclusive, worldwide, royalty-bearing license agreement with SciSparc Ltd. for its SCI-160 platform.
• Manufacturing & R&D Partnerships: Engaged Eurofins Amatsiaquitaine S.A.S. (European-based GMP manufacturer) for clinical trial material supply. Collaborates with Professor Fabio Sonvico (University of Parma, Italy) on T&T platform development.

Cross-Border Trade:

• Export Markets: Not applicable, as the company has no product sales.
• Import Dependencies: Relies on third-party suppliers for raw materials necessary for product candidate manufacturing.
• Transfer Pricing: Mentioned as a risk factor and part of international tax strategy, particularly in relation to IIA grants and potential transfer of know-how or manufacturing outside Israel, which may incur increased royalties or redemption fees. Specific policies or transactions are not detailed.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not applicable (none disclosed).
• Dividend Payments: $0. The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future, intending to retain future earnings for business development.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $2.55 million (as of December 31, 2024)
• Total Debt: $0 (convertible loans of $0.25 million and $0.60 million were repaid in October 2024 in connection with the IPO; 2023 convertible notes of $0.18 million converted into ordinary shares in May 2024).
• Net Cash Position: $2.55 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: No significant debt maturities as of December 31, 2024, due to repayment and conversion of convertible loans.

Cash Flow Generation:

• Operating Cash Flow: $(1.15) million (used in operating activities for the year ended December 31, 2024)
• Free Cash Flow: $(1.12) million (Operating Cash Flow of $(1.147) million + Net cash from investing activities of $0.029 million)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Currency Management:

• Cash holdings by major currencies: Not explicitly detailed.
• Natural hedging through operational diversification: Not explicitly detailed as a strategy, but mentioned as a potential risk mitigation in the template.
• Financial hedging instruments and strategies: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Polyrizon Ltd. is a development-stage biotech company. Its production and service model is currently focused on research and development, with a reliance on third parties for manufacturing and clinical trial execution. The company is establishing its own cGMP-compliant manufacturing capabilities but intends to continue relying on third-party suppliers for raw materials and manufacturing for clinical and commercial scale.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Clinical Trial Material (CTM) Manufacturer: Eurofins Amatsiaquitaine S.A.S. (European-based GMP manufacturer) - engaged for CTM supply for PL-14 allergy blocker.
• Pre-clinical Contract Research and Development Organization (CRDO): PharmaSeed Ltd. (Israel’s largest GLP-certified pre-clinical CRDO) - conducted efficacy and cytotoxicity studies for C&C formulations.
• Raw Material Suppliers: Relies on third-party suppliers for raw materials, some of which will need to become cGMP-compliant and establish a drug master file for T&T platform product candidates.

Facility Network:

• Manufacturing: Currently relies on third parties. Plans to establish own cGMP-compliant manufacturing capabilities.
• Research & Development: Leases approximately 25 square meters (270 square feet) in Rehovot, Israel. Focus areas include C&C hydrogel technology and T&T drug delivery system. Collaborates with Professor Fabio Sonvico (University of Parma, Italy) on T&T development.
• Distribution: Not applicable, as no products are approved for commercialization.

Operational Metrics: Not explicitly detailed in the filing (e.g., capacity utilization, efficiency measures, quality indicators).

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Currently has no marketing and sales organization. If product candidates receive regulatory approval, the company intends to establish a sales and marketing organization independently.
• Channel Partners: May utilize experienced third parties with technical expertise and supporting distribution capabilities to commercialize product candidates in major markets. May enter into collaborations with other entities for local marketing and distribution.
• Digital Platforms: Not explicitly detailed in the filing.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Not applicable, as no products are approved for commercialization.
• Strategic Partnerships: SciSparc Ltd. (for SCI-160 platform).
• Customer Concentration: Not applicable.

Regional Market Penetration:

• Not applicable: The company has no product sales or market share data.
• Growth Markets: Focus on obtaining regulatory approvals in the United States and the European Union to penetrate these key markets.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The medical device and pharmaceutical industries are intensely competitive, characterized by rapid technological change and the constant introduction of new products. Markets for nasal sprays, COVID-19 therapeutics, cold and cough remedies, allergic rhinitis, allergen blockers, intranasal drug delivery, intranasal corticosteroids (INCS), benzodiazepines, and naloxone are substantial and growing.

• Nasal Spray Market: Expected to reach $49.54 billion by 2030, growing at an 8.8% CAGR (2023-2030).
• COVID-19 Therapeutics Market: Forecasted to reach $16.2 billion in 2031.
• Cold and Cough Remedies Market: Valued at $42.65 billion in 2024, expected to grow at a CAGR of 6.18% (2024-2029).
• Allergic Rhinitis Drugs Market: Projected to reach $16 billion by 2032, growing at a CAGR of 2.5% (2023-2032).
• Allergen Blocker Market: Expected to reach $214.5 million in 2030, growing at a CAGR of 3.64% (2023-2030).
• Intranasal Drug Delivery Market: Projected to reach $136.46 billion by 2032, growing at a CAGR of 7.18%.
• Intranasal Corticosteroids Market: Estimated to reach $11.2 billion by 2033.
• Benzodiazepine Drugs Market: Expected to reach $4.2 billion by 2032, reflecting a CAGR of 3.7% (2024-2032). The market for Benzodiazepines for seizure clusters is estimated around $700 million.
• Naloxone Market: Expected to grow to $2.47 billion in 2032, at a CAGR of 11% (2023-2032). The naloxone intranasal spray market alone is projected to attain $1.4 billion by 2030.
• Pain Management Drugs Market: Estimated at $78.14 billion in 2022 and projected to hit around $115 billion by 2032, growing at a CAGR of 3.94% (2023-2032).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Nasal Barrier Products (C&C): Alzair, Nasalese, Bentrio.
• Intranasal Corticosteroids (T&T): Sanofi, GlaxoSmithKline plc., Merck Sharp Dohme, McNeil Consumer Healthcare, Sunovion Pharmaceuticals Inc, Teva Branded Pharm, Ivax Pharmaceuticals Incorporated, AstraZeneca, and other small/local manufacturers.
• Intranasal Benzodiazepines (T&T): UCB Biopharma SPRL (Nayzilam®).
• Intranasal Naloxone (T&T): Emergent BioSolutions, Pfizer, Teva Pharmaceutical Industries Ltd., Opiant Pharmaceuticals, Hikma Pharmaceuticals, Nasus Pharma, Amphastar Pharmaceuticals, Indivior PLC, Samarth Pharma Pvt. Ltd., Troikaa Pharmaceuticals Ltd., Neon Laboratories Limited (including Narcan®, Kloxxado®).
• General: Major multinational medical device and pharmaceutical companies, public and private universities, and research organizations with greater financial, technical, manufacturing, marketing, and human resources.

Regional Competitive Dynamics: Competition varies by region, with established players dominating existing markets. Polyrizon Ltd. aims to enter the US and EU markets, facing strong competition from companies with extensive marketing and sales operations.

Risk Assessment Framework

Strategic & Market Risks

• Global Market Dynamics: The company is a development-stage biotech company with no revenue, incurring significant losses and dependent on successful development, regulatory approval, and commercialization of novel technologies. Market acceptance of new product candidates is uncertain.
• Technology Disruption: Operates in an environment of rapid technological change; competitors may develop superior or more cost-effective products.
• Customer Concentration: Not applicable, as no products are currently commercialized.

Operational & Execution Risks

• Global Supply Chain Vulnerabilities: Heavy reliance on third parties for raw materials and manufacturing (e.g., Eurofins). Disruptions or failures by these third parties could delay development and commercialization.
• Regional Disruptions: Operations in Israel expose the company to political, economic, and military instability, including the recent conflict with Hamas. While operations have not been adversely affected to date, escalation could impact business conditions, employee availability, and ability to raise capital.
• Trade Restrictions: Not explicitly detailed, but general trade restrictions could impact international operations.
• Supplier Dependency: Reliance on a limited number of third-party service providers and vendors for preclinical and clinical trials, and raw materials.
• Patient Enrollment: Difficulties in recruiting and retaining patients for clinical trials could delay or terminate development programs.
• Undesirable Side Effects: Product candidates may cause side effects, leading to clinical trial delays/halts, restrictive labeling, or post-marketing consequences.
• Organizational Growth: Need to expand organization and manage growth, which could divert management attention and strain resources.
• Resource Allocation: Limited resources necessitate prioritization of product candidates, and incorrect decisions could adversely affect future revenues.
• Employee Misconduct: Risk of fraud or misconduct by employees and independent contractors, including non-compliance with regulatory standards and healthcare fraud and abuse laws.
• Environmental, Health, and Safety Compliance: Research, development, and manufacturing involve hazardous materials, subject to stringent environmental, health, and safety laws. Non-compliance could lead to fines or operational disruptions.

Financial & Regulatory Risks

• Currency & Financial Risks: Exposure to foreign currency exchange fluctuations (NIS, EUR vs. USD) affecting costs.
• Interest Rate Risk: Not explicitly detailed, but general economic conditions and interest rate increases could impact financing.
• Credit & Liquidity: Significant losses and negative cash flows since inception. Requires substantial additional funding, which may not be available on acceptable terms, raising substantial doubt about its ability to continue as a going concern beyond October 2025.
• Regulatory & Compliance Risks: Lengthy, costly, and unpredictable regulatory approval processes (FDA, EMA). Potential for delays, denials, or restrictive approvals. Subject to U.S. federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws, and health information privacy/security laws.
• Multi-Jurisdictional Compliance: Compliance with varying regulatory requirements across countries (e.g., EU Medical Devices Regulation).
• Trade Regulations: Not explicitly detailed, but general trade regulations could impact operations.
• Tax Regulations: Potential for classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse consequences for U.S. Holders. Israeli government grants impose restrictions on manufacturing and technology transfer outside Israel, potentially requiring additional payments.

Geopolitical & External Risks

• Country-Specific Risks (Israel): Headquarters and operations in Israel are subject to political, economic, and military instability. Armed conflicts, terrorist activities, or political unrest could adversely affect business conditions, operations, and ability to raise capital. Commercial insurance does not cover war-related losses, and government coverage may be insufficient.
• Economic Risk: Adverse global economic and market conditions, inflation, and interest rate increases could negatively affect business, operating results, and ability to secure financing.
• Regulatory Changes: Legislative or regulatory reforms in the U.S. or EU (e.g., ACA, IRA, changes to 510(k) process, MDR) could increase costs, delay approvals, or impact market access. Disruptions at government agencies (e.g., FDA shutdowns) could hinder timely review of submissions.

Innovation & Technology Leadership

Research & Development Focus: Global R&D Network:

• Rehovot, Israel: Primary R&D facility and laboratory.
• Innovation Pipeline:
  • Capture and Contain (C&C) Technology: Developing hydrogel-based nasal sprays (PL-14, PL-15, PL-16) to create a physical barrier against allergens, influenza, and COVID-19. Focus on mucoadhesive polymers optimized for coverage, adherence, and capturing biological assaults.
  • Trap and Target (T&T) Technology: Developing a platform for sustained intranasal delivery of APIs. Focus on tailoring physicochemical properties (composition, concentration, crosslinking) for long residence time and intimate contact with mucosal tissue. Initial feasibility studies for corticosteroids, benzodiazepines, and naloxone.
  • SCI-160 Platform: Exploring potential when combined with T&T technology for pain solutions, under an exclusive license from SciSparc Ltd.

Intellectual Property Portfolio:

• Patent Strategy: Relies on a combination of patents, trade secret protection, and confidentiality agreements. Has a single patent family disclosing its technology, with 5 national phase applications filed as of March 10, 2025, in Israel, Europe, Japan, Singapore, and the U.S., covering mucoadhesive polymers for nasal drug delivery.
• Licensing Programs: SciSparc License Agreement for SCI-160 platform.
• IP Litigation: Not currently involved in any legal proceedings.

Technology Partnerships:

• Strategic Alliances: SciSparc Ltd. (exclusive license for SCI-160 platform).
• Research Collaborations: PharmaSeed Ltd. (GLP-certified pre-clinical CRDO for in-vitro blocking assays). Professor Fabio Sonvico (University of Parma, Italy, and Scientific Advisory Board member) for T&T platform development, including Naloxone studies.

Leadership & Governance

Executive Leadership Team

International Management Structure: The company's executive officers and directors are primarily residents of Israel. Regional leadership and reporting relationships are not explicitly detailed beyond the Israeli base.

Board Composition: The board of directors consists of seven members: Tomer Izraeli, Oz Adler, Asaf Itzhaik, Omer Srugo, Liat Sidi, Yehonatan Zalman Vinokur, and Liron Carmel. Four directors (Asaf Itzhaik, Omer Srugo, Liat Sidi, Yehonatan Zalman Vinokur) are independent under Nasdaq Stock Market rules. The board is divided into three classes with staggered three-year terms. The company has elected to "opt out" from the Israeli Companies Law requirement to appoint external directors and related rules concerning audit and compensation committee composition, leveraging its foreign private issuer status.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework:

• United States (FDA): C&C product candidates are expected to be regulated as Class II medical devices. PL-14 is pursuing the 510(k) pathway, while PL-15 and PL-16 are pursuing the De Novo Classification pathway. T&T product candidates are expected to be regulated as drug-device combination products, pursuing the FDA’s 505(b)(2) pathway. Compliance with Investigational Device Exemption (IDE) regulations for clinical trials and current Good Manufacturing Practices (cGMP) is required.
• European Union (EMA/EU Medical Devices Regulation): Product candidates must comply with the general safety and performance requirements of the EU Medical Devices Regulation (Regulation (EU) No 2017/745) to affix the CE mark, which is a prerequisite for sale in the EU and EEA. This involves conformity assessment procedures, potentially requiring a notified body.
• Israel (MOH): Subject to regulatory approvals from the Israeli Ministry of Health for manufacturing processes and facilities.

Cross-Border Compliance:

• Export Controls: Not explicitly detailed, but generally subject to technology transfer restrictions and licensing requirements for cross-border movement of technology.
• Sanctions Compliance: Not explicitly detailed, but multi-jurisdictional sanctions compliance is a general risk for international operations.
• Anti-Corruption: Subject to U.S. federal and state healthcare fraud and abuse laws, including the U.S. Anti-Kickback Statute and False Claims Act, and analogous state and foreign laws. Compliance with the Physician Payments Sunshine Act and HIPAA privacy/security standards is also required.

International Tax Strategy:

• Transfer Pricing: Mentioned as a risk factor, particularly concerning IIA grants and the potential transfer of manufacturing or know-how outside Israel, which may trigger increased royalties or redemption fees.
• Tax Treaties: The U.S.-Israel Tax Treaty may provide exemptions or credits for U.S. residents on Israeli capital gains tax and withholding tax on dividends, subject to specific conditions.
• BEPS Compliance: Not explicitly detailed, but general compliance with Base Erosion and Profit Shifting (BEPS) regulations is a consideration for international tax planning.

Environmental & Social Impact

Global Sustainability Strategy: Not explicitly detailed in the filing. The company acknowledges scrutiny related to ESG practices and disclosures as a potential risk factor, which could lead to increased costs or adverse impacts.

Environmental Commitments: Not explicitly detailed in the filing. The company's research, development, and manufacturing activities involve hazardous materials, subjecting it to environmental laws and regulations concerning their use, storage, handling, and disposal.

Regional Sustainability Initiatives: Not explicitly detailed in the filing.

Social Impact by Region: Not explicitly detailed in the filing. The company is subject to Israeli labor laws and regulations.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies:

• Transaction Hedging: Not explicitly detailed in the filing.
• Translation Hedging: Not explicitly detailed in the filing.
• Economic Hedging: Not explicitly detailed in the filing. The company notes that currency fluctuations could affect costs and that an inability to offset higher costs through hedging transactions could harm the business.